Physician profile
Travis Westermeyer
NPI 1538122718
$158,309.97
in general payments reported to CMS, 2019-2025
7 companies · $148K in 2025
The $148K reported for 2025 was more than what 99% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $164 · 2021: $122 · 2022: $24.91 · 2023: $15.85 · 2024: $9,679 · 2025: $148K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $120K · Consulting Fee: $21K · Travel and Lodging: $16K · Food and Beverage: $539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $120,000.00 |
| Consulting Fee | $21,262.80 |
| Travel and Lodging | $16,018.68 |
| Food and Beverage | $539.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $157,967.50 | 2021-2025 | Easyfuse, Prostep, Variax |
| Wright Medical Technology, INC. | $131.64 | 2020 | |
| Smith+Nephew, INC. | $72.53 | 2019 | |
| Zimmer Biomet Holdings, INC. | $58.36 | 2019-2020 | |
| Misonix INC | $45.10 | 2019 | |
| Integra Lifesciences Corporation | $20.96 | 2019 | |
| Melinta Therapeutics, LLC | $13.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Westermeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.